title: Membrane-associated matrix proteolysis and heart failure.
abstract: The extracellular matrix (ECM) is a complex entity containing a large portfolio of structural proteins, signaling molecules, and proteases. Changes in the overall integrity and activational state of these ECM constituents can contribute to tissue structure and function, which is certainly true of the myocardium. Changes in the expression patterns and activational states of a family of ECM proteolytic enzymes, the matrix metalloproteinases (MMPs), have been identified in all forms of left ventricle remodeling and can be a contributory factor in the progression to heart failure. However, new clinical and basic research has identified some surprising and unpredicted changes in MMP profiles in left ventricle remodeling processes, such as with pressure or volume overload, as well as with myocardial infarction. From these studies, it has become recognized that proteolytic processing of signaling molecules by certain MMP types, particularly the transmembrane MMPs, actually may facilitate ECM accumulation and modulate fibroblast transdifferentiation; both are critical events in adverse left ventricle remodeling. Based on the ever-increasing substrates and diversity of biological actions of MMPs, it is likely that continued research about the relationship of left ventricle remodeling in this family of proteases will yield new insights into the ECM remodeling process and new therapeutic targets.
authors.affiliation: Cardiovascular Translational Research Center, CBA, University of South Carolina School of Medicine, 6439 Garners Ferry Rd, Columbia, SC, USA. cvctrc@uscmed.sc.edu
authors.forename: Francis G
authors.initials: FG
authors.lastname: Spinale
authors.forename: Joseph S
authors.initials: JS
authors.lastname: Janicki
authors.forename: Michael R
authors.initials: MR
authors.lastname: Zile
mesh_terms: D000818:Animals; D054338:Cell Transdifferentiation; D005109:Extracellular Matrix / Q000378:metabolism*; D005355:Fibrosis; D015971:Gene Expression Regulation, Enzymologic; D006333:Heart Failure / Q000201:enzymology* / Q000235:genetics / Q000473:pathology / Q000503:physiopathology / Q000628:therapy; D006439:Hemodynamics; D006801:Humans; D020782:Matrix Metalloproteinases / Q000235:genetics / Q000378:metabolism*; D009206:Myocardium / Q000201:enzymology* / Q000473:pathology; D058628:Myofibroblasts / Q000201:enzymology / Q000473:pathology; D011379:Prognosis; D015398:Signal Transduction; D013379:Substrate Specificity; D020257:Ventricular Remodeling
chemical_list: D020782:Matrix Metalloproteinases